Key result
Minimally invasive direct coronary artery bypass (MIDCAB) was associated with better 7-year LVEF and vessel patency rates compared to median sternotomy off-pump CABG (p<0.05).
Why the study?
The study was conducted to investigate the clinical significance of minimally invasive direct coronary artery bypass.
Does MIDCAB improve perioperative outcomes and mid-term vessel patency compared to median sternotomy OPCAB in patients undergoing off-pump coronary artery bypass?
Cohort (n=300)
No
Does MIDCAB improve perioperative outcomes and mid-term vessel patency compared to median sternotomy OPCAB in patients undergoing off-pump coronary artery bypass?
p-value: p=<0.05
MIDCAB offers a safe and effective alternative to traditional median sternotomy OPCAB, with improved perioperative recovery and favorable 7-year vessel patency.
No takes yet. Share an insight, caveat, or question.
Supports MIDCAB consideration in selected patients; leaves open confirmation of long-term benefits in randomized trials.
Xu et al. (2019) conducted a cohort in Coronary artery disease requiring bypass surgery (n=300). Minimally invasive direct coronary artery bypass (MIDCAB) vs. Median sternotomy off-pump coronary artery bypass (OPCAB) was evaluated on Perioperative outcomes, 7-year LVEF, and vessel patency rate (p=<0.05). Minimally invasive direct coronary artery bypass (MIDCAB) was associated with better 7-year LVEF and vessel patency rates compared to median sternotomy off-pump CABG (p<0.05).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: